ProCE Banner Activity

Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma

Slideset Download
Conference Coverage
Idecabtagene vicleucel therapy resulted in CR/sCR responses in one third of patients with heavily pretreated R/R MM with durability approaching 2 years.

Released: June 04, 2020

Expiration: June 03, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono